news/blog

corporate

English

CookieConsent

The domain 'www.biospace.com' uses the commercial generic top-level domain (.com), featuring subdomain 'www'. Count 8 characters in 'biospace' split between 4 vowels and four consonants. Word splitting yields 2 words: bio, space. Expect four characters per word on average. No strong language cues emerged from the frequency lists.

html/72/53/72539f36-2cec-41ae-91dd-61446e9ff7e2_fallback.html.gz

J&amp;J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash - BioSpace

html/72/53/72539f36-2cec-41ae-91dd-61446e9ff7e2.html.gz

appId=cid-v1:89f47f4b-bed0-4db8-956b-d6e6dfac3fef

script-src 'none'; form-action 'none'; frame-src 'none'; report-uri https://csp.withgoogle.com/csp/scaffolding/ascgsrsghrgc:72:0

script-src 'none'; form-action 'none'; frame-src 'none'; report-uri https://csp.withgoogle.com/csp/scaffolding/ascnsrsggc:106:0

Blank

2a85d44e869659f2c40a78820bfb32c673575c923997127cf0ed587993a49094

88354a095d91d539a0e119b90a1f847de376bc74d54b326ff0ee51c03998836e

a2a0c43d810399c64e0d3c2335822ca08dcb7344d15a182ce60daa50aa550647

b161465633296cc6b8ce5860caefca89c28f1567e16e0447c8d12cb665e03c84

7d9c943f28402d1439639ce454fcde2700c6b85bc19c7f08ca026bc9abab575c

1b6f1a4263197f2c1249fe4ddc862303f558b6e8c30bca33a7fdf230831a915a

f3f007554f23d799cc857bdc2f99f15b96d2cad06478190021275f12407d6d27

a89881560c77b1a6e5260763c747e15708565f025ab634ea3909f23c2b83c82e

257bc323409735fd930f1fe1d667d05c828a592760beed97931531fab47102bc

bc34a3c1a0d8aa0a4158d9575dc08cea57a58c1b8cd95e75bdab416fa9e7c79c

7ee4dc950437cc255d21a18d5c44bf1a944eba13a1c12ada74536b58aff7071f

3a04fc008338e4ee4cd3f9ece3795ab80bf9f9112714a30cc045336ad569f3a7

94204b9679d3827edf014714eb311bfb11f5c342a27fd9025be0cd3502f9b993

1f4a4eab87455713703be578b55ee0b90f29bfb65d93133f4571429f6338a572

527ad9ff29a2bdf036db3735dbcf7752a1e8906c4a73961f58559187d9d2bca5

4e151fafa1909092a23469158dd5e2028472fc647c22354db789e3a3845333a0

6ed6599f399ffbcc2a7fb88541651435aab56e8ae25def3ce251725d43117008

b1e578161f595a12f50d73336ddf057e87aef4963703ac15dfb92c9b90c01fde

2d25441c0d6a4dda2a379b73c3d09e2208f7c1ffc2d33fa5bf3824fa9a495bde

68d3c055ce6b4707004a49bace3efb0c53519708a2308a27a4838bfb6f0aa45b

704fe03c88967b21dc31ec8f14c0558f69cb2d223aa1e0b0d1eba35a8d7ea786

68682417e57ebfd06f5b9e10fce969291ebbfd36db36bcf46611d0de49548dc7

0919caaafce8984f9074e0e2f14ca9aea23a375624cdb4d6bc3139b44f9ae07f

3a77234469d653befcd8250c555ea3430f6591db783e948b75e28e4e3a44e678

0169c47dcdd5dd25b042a3e15778feaa98d85490100a0122a81d9c8eaa2b410a

J&J, Aiming for $50B in Cancer Sales, Buys Halda for $3B in Cash

https://www.biospace.com/business/j-j-aiming-for-50b-in-cancer-sales-buys-halda-for-3b-in-cash

https://static.biospace.com/dims4/default/1855896/2147483647/strip/true/crop/2000x1125+0+104/resize/1440x810!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2F86%2F0d%2F65b5b95e4f429abd29d4e84468ef%2Fjnj-image-2.jpg

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ambitious goal for its oncology sales by 2030.

https://www.biospace.com/dan-samorodnitsky

twitter:card

twitter:description

twitter:image

twitter:image:alt

twitter:site

twitter:title

width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=5

viewport

description

brightspot.contentId

AlK2UR5SkAlj8jjdEc9p3F3xuFYlF6LYjAML3EOqw1g26eCwWPjdmecULvBH5MVPoqKYrOfPhYVL71xAXI1IBQoAAAB8eyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ==

Amm8/NmvvQfhwCib6I7ZsmUxiSCfOxWxHayJwyU1r3gRIItzr7bNQid6O8ZYaE1GSQTa69WwhPC9flq/oYkRBwsAAACCeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ==

A9nrunKdU5m96PSN1XsSGr3qOP0lvPFUB2AiAylCDlN5DTl17uDFkpQuHj1AFtgWLxpLaiBZuhrtb2WOu7ofHwEAAACKeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

A93bovR+QVXNx2/38qDbmeYYf1wdte9EO37K9eMq3r+541qo0byhYU899BhPB7Cv9QqD7wIbR1B6OAc9kEfYCA4AAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

A1S5fojrAunSDrFbD8OfGmFHdRFZymSM/1ss3G+NEttCLfHkXvlcF6LGLH8Mo5PakLO1sCASXU1/gQf6XGuTBgwAAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

HSTS header missing - vulnerable to protocol downgrade attacks

CSP header missing - vulnerable to XSS attacks

child-src 'none';object-src 'none';require-trusted-types-for 'script';script-src chrome://resources 'self';trusted-types;worker-src blob: 'self';frame-ancestors 'none';

child-src https:  chrome-untrusted://new-tab-page/ chrome-untrusted://ntp-microsoft-auth/;connect-src chrome://resources chrome://theme 'self';default-src 'self';font-src chrome://resources 'self';img-src chrome://resources chrome://theme chrome://image chrome://favicon2 chrome://app-icon chrome://extension-icon chrome://fileicon blob: data: 'self';object-src 'none';require-trusted-types-for 'script';script-src chrome://resources chrome://webui-test 'self';style-src chrome://resources chrome://theme 'self' 'unsafe-inline';trusted-types parse-html-subset sanitize-inner-html static-types webui-test-script webui-test-html polymer-html-literal polymer-template-event-attribute-policy lit-html-desktop;frame-ancestors 'none';

child-src 'none';object-src 'none';require-trusted-types-for 'script';script-src chrome://resources 'self';trusted-types;frame-ancestors 'none';

base-uri 'none';child-src https:;form-action https://ogs.google.com https://*.corp.google.com;object-src 'none';script-src 'self' 'unsafe-inline' https:;frame-ancestors chrome://new-tab-page/

GoDaddy.com, LLC

BIOSPACE.COM

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson &amp; Johnson set an ambitious goal for its oncology sales by 2030. Johnson & Johnson is plunking down $3.05 billion in cash to acquire Halda Therapeutics in a play to beef up its cancer pipeline. The acquisition brings Halda’s pipeline of oral therapies for treating solid tumors to J&J, according to Monday morning’s announcement. Halda’s lead candidate is HLD-0915, a once-daily oral therapy for prostate cancer that was granted fast track designation from the FDA in August. Phase I/II data presented in late 2024 “showed encouraging preliminary signs of anti-tumor activity,” lowering prostate cancer biomarkers and achieving partial responses in five out of five patients. The company’s Phase I/II trial for metastatic, castration-resistant prostate cancer (mCRPC) is still ongoing. “This acquisition further strengthens our deep oncology pipeline with an exciting lead asset in prostate cancer and a platform capable of treating multiple cancers and diseases beyond oncology, providing a potential mid- and long-term catalyst for growth,” Jennifer Taubert, J&J’s executive vice president of Innovative Medicine, said in a statement. During a second-quarter earnings call this past July, CEO Joaquin Duato announced a target of $50 billion in oncology sales by 2030. Feeding into that, Halda brings a development platform called Regulated Induced Proximity Targeting Chimera, or RIPTAC, which the company uses to design linked ligands that target two different proteins: a tumor-specific protein and another protein with an essential function. The goal is to kill tumor cells while sparing non-cancerous cells. Halda refers to all of its drugs as RIPTACs. Other drugs in the pipeline include a breast cancer drug targeting hormone receptor positive (HR+) tumors, an asset being tested in lung cancer and other undisclosed therapies. For Halda, the acquisition represents a swift return on investment. The company launched in 2019 out of the lab of Yale chemistry professor Craig Crews. Halda received strong attention from investors, most recently getting a second series B raise of $126 million to push HLD-0915, as well as an unnamed breast cancer asset, forward in development. For J&J, the Halda acquisition is the second major acquisition deal this year after the $14.6 billion purchase of neuropsychiatric-focused Intra-Cellular Therapies in January—which still ranks as the largest pharma M&A deal of the year. J&J promised that the rest of 2025 would be quiet for business development. J&J and Halda expect the deal to close “within the next few months,” after antitrust clearance and other closing conditions are met, according to the announcement. J&J said it would provide an update at fourth quarter earnings in late January 2026.

BioSpace

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. 


        /**
            This allows us to load the IE polyfills via feature detection so that they do not load
            needlessly in the browsers that do not need them. It also ensures they are loaded
            non async so that they load before the rest of our JS.
        */
        var head = document.getElementsByTagName('head')[0];
        if (!window.CSS || !window.CSS.supports || !window.CSS.supports('--fake-var', 0)) {
            var script = document.createElement('script');
            script.setAttribute('src', "https://static.biospace.com/resource/0000018c-e9c4-deef-a1fd-fbfe1e4b0000/util/IEPolyfills.min.4e804e24ca7aa61e14b66eca853bb6e7.gz.js");
            script.setAttribute('type', 'text/javascript');
            script.async = false;
            head.appendChild(script);
        }
    


    // Google tag setup
    var googletag = googletag || {};
    googletag.cmd = googletag.cmd || [];

    googletag.cmd.push(function () {
        googletag.pubads().enableSingleRequest()
        googletag.pubads().enableAsyncRendering()
        googletag.pubads().disableInitialLoad()
        googletag.enableServices()
    })

    // setup of ad slots
    var dfpAdSlotsObject = {}
    var dfpAdSlots = []
    var staticAdSlots = []


var script = document.createElement('script');
script.async = true;
script.src = 'https://analytics.ahrefs.com/analytics.js';
script.setAttribute('data-key', 'ijoT0Tuv31/VTArPbpYiGg');
document.getElementsByTagName('head')[0].appendChild(script);

window.dataLayer = window.dataLayer || [];
const pageType = document.documentElement.className || 'Page';

window.dataLayer.push({
    event: 'gtm_data_load',
    page_type: pageType
});


        var link = document.createElement('link');
        link.setAttribute('href', '//fonts.googleapis.com/css?family=Helvetica:300,400,700|Merriweather:300,400,700&display=swap');
        var relList = link.relList;

        if (relList && relList.supports('preload')) {
            link.setAttribute('as', 'style');
            link.setAttribute('rel', 'preload');
            link.setAttribute('onload', 'this.rel="stylesheet"');
            link.setAttribute('crossorigin', 'anonymous');
        } else {
            link.setAttribute('rel', 'stylesheet');
        }

        head.appendChild(link);
    

(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
                new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
            j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
            'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
    })(window,document,'script','dataLayer','GTM-NBF2TMB');

 
            hbspt.forms.create({ 
                region: "na1", 
                portalId: "4413123", 
                formId: "0a23f86f-1028-4c28-aa02-58fc7c33f16e",
                          onFormSubmitted: function($form, data) {
      window.dataLayer = window.dataLayer || [];
      window.dataLayer.push({
        'event': 'GTMevent',
        'event_name': 'newsletter_sign_up'
          
      });
    }
  });


$("#social-buttons a, .share-buttons a").on("click",function(){ClientGoogleTagManagerDataLayer.push({event:"social button click","social button":$(this).text()})});

Consent Management Platform

Google

First-Party Tracking

✅ Low Risk - https://www.biospace.com/business/j-j-aiming-for-50b-in-cancer-sales-buys-halda-for-3b-in-cash

Requests	IP Address	Location	AS Autonomous System
53	142.250.185.194	Unknown	Unknown
0	142.250.185.232	Unknown	Unknown
0	3.167.227.32	Unknown	Unknown
0	23.50.131.141	Unknown	Unknown
0	142.250.185.168	Unknown	Unknown
0	2.17.190.7	Unknown	Unknown
0	142.250.186.42	Unknown	Unknown
0	104.16.5.65	Unknown	Unknown
0	18.245.46.35	Unknown	Unknown
0	3.167.227.29	Unknown	Unknown
53	54	-	-

Security Scan Report: www.biospace.com

Summary

AI Security Verdict

Safe Website

Safety Factors

Details

Screenshot

Page Load Overview

Language Analysis

Primary Language

Detection Details

Website Classification

Primary Category

All Detected Categories

Detected Features

Domain & IP Information

Content Similarity HashesFor malware variant detection

TLSH (Trend Micro Locality Sensitive Hash)

ssdeep (Context Triggered Piecewise Hashing)

sdhash (Similarity Digest Hashing)

Image Hashes

Perceptual Hashes

Other Hashes

Scan History